Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is an open label, Phase One, multicenter study, designed to evaluate the safety,
tolerability, to explore the biologic effects, and to explore the clinical effects of the
following doses of IW001: 0.1mg/day, 0.5 mg/day, and 1.0 mg/day, when administered once a day
orally for 24 weeks in patients with IPF.